APA (7th ed.) Citation

H, A., & B, S. (2026). Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. Current oncology (Toronto, Ont.), 33(7), . https://doi.org/10.3390/curroncol33070421

Chicago Style (17th ed.) Citation

H, Abdel-Razeq, and Sharaf B. "Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms." Current Oncology (Toronto, Ont.) 33, no. 7 (2026). https://doi.org/10.3390/curroncol33070421.

MLA (9th ed.) Citation

H, Abdel-Razeq, and Sharaf B. "Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms." Current Oncology (Toronto, Ont.), vol. 33, no. 7, 2026, https://doi.org/10.3390/curroncol33070421.